Business, energy, technology, markets and global industry news from Business News Today

Apnimed

PharmaDeviceNews Apnimed
Representative image: Apnimed, Inc. has filed for a Nasdaq IPO as investors weigh the commercial potential and FDA approval prospects of AD109, its once-nightly oral treatment for obstructive sleep apnea.
Pharma & Biotech

Apnimed files for Nasdaq IPO as oral sleep apnea drug AD109 nears FDA review

Apnimed, Inc. has filed for an initial public offering in the United States as it prepares for a potentially decisive regulatory year for AD109, its once-nightly oral treatment for obstructive sleep apnea. The Cambridge, Massachusetts-based pharmaceutical company plans to list on the Nasdaq Global Market under the ticker APMD, although the number of shares, proposed

Read More
Representative image of a sleep medicine setting as Apnimed’s AD109 oral therapy advances debate over obstructive sleep apnea treatment, Phase 3 data, and potential FDA review.
Pharma & Biotech

Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window

Find out how Apnimed’s AD109 Phase 3 data could reshape oral treatment for obstructive sleep apnea as FDA review approaches.

Read More